Teacher Retirement System of Texas Makes New $106,000 Investment in Annexon, Inc. (NASDAQ:ANNX)

Teacher Retirement System of Texas purchased a new stake in Annexon, Inc. (NASDAQ:ANNX) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 20,568 shares of the company’s stock, valued at approximately $106,000.

Other institutional investors have also modified their holdings of the company. Intech Investment Management LLC acquired a new stake in shares of Annexon during the third quarter worth $154,000. Charles Schwab Investment Management Inc. increased its stake in shares of Annexon by 221.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock worth $4,335,000 after purchasing an additional 504,656 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Annexon by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after acquiring an additional 2,450 shares during the last quarter. FMR LLC boosted its position in Annexon by 3.2% during the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after acquiring an additional 262,229 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in Annexon by 11.8% during the third quarter. MetLife Investment Management LLC now owns 55,212 shares of the company’s stock worth $327,000 after buying an additional 5,814 shares in the last quarter.

Annexon Stock Up 8.3 %

NASDAQ:ANNX opened at $1.96 on Thursday. Annexon, Inc. has a 52 week low of $1.73 and a 52 week high of $7.85. The company has a fifty day simple moving average of $2.91 and a two-hundred day simple moving average of $4.88. The company has a market cap of $215.03 million, a price-to-earnings ratio of -1.87 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ANNX shares. Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.